batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. Teneobio falls short of Amgen’s expectations 31 October 2023 Loqtorzi becomes ninth US anti-PD-(L)1 drug 30 October 2023 Deciphera sets sights on a second marketed drug 30 October 2023 AstraZeneca goes early with new datopotamab breast phase 3s 26 October 2023 ESMO 2023 – how datopotamab's lung side effects are graded 24 October 2023 ESMO 2023 – Nectin-4 in focus 24 October 2023 ESMO 2023 – BioNTech still has work to do on Claudin6 24 October 2023 ESMO 2023 – more hope for a new Car-T target 23 October 2023 Load More